Table 3 Median overall survival from the time of hypofractionated stereotactic radiotherapy (HFSRT) in subgroups of patients with recurrent malignant glioma.
From: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
n | median (range) overall survival (months) | p | |
|---|---|---|---|
WHO grade (initial histopathology) | |||
II or III | 10 | 13.5 (1.9–77.6) | 0.036 |
IV | 9 | 7.4 (4.2–10.8) | |
WHO grade (most recent before HFSRT) | |||
III | 5 | 15.4 (1.9–77.6) | 0.029 |
IV | 14 | 7.9 (4.2–38.8) | |
initial surgical procedure | |||
biopsy | 15 | 9.3 (4.2–77.6) | 0.89 |
resection | 4 | 9.2 (1.9–34.6) | |
chemotherapy before HFSRT | |||
yes | 13 | 9.3 (1.9–77.6) | 0.76 |
no | 6 | 8.9 (7.3–15.4) | |
reoperation before HFSRT | |||
yes | 12 | 8.4 (1.9–77.6) | 0.93 |
no | 7 | 9.3 (5.6–34.6) | |
age at time of HFSRT | |||
< 50 years | 11 | 11.9 (1.9–77.6) | 0.14 |
> 50 years | 8 | 8.9 (5.0–11.1) | |
Karnofsky performance score at time of HFSRT | |||
≥ 90 | 14 | 7.9 (4.2–77.6) | 0.80 |
< 90 | 5 | 11.9 (1.9–15.4) | |
planning target volume (ml) | |||
< 15 ml | 9 | 9.3 (5.2–38.8) | 0.59 |
> 15 ml | 10 | 7.4 (1.9–77.6) | |
interval first RT series to HFSRT | |||
> 20 months | 9 | 7.4 (1.9–77.6) | 0.90 |
< 20 months | 10 | 9.3 (5.6–38.8) | |
total HFSRT dose | |||
30 Gy | 11 | 11.1 (1.9–77.6) | 0.051 |
< 30 Gy | 8 | 7.4 (4.2–11.9) | |
chemotherapy after HFSRT | |||
yes | 13 | 9.3 (1.9–77.6) | 0.27 |
no | 6 | 8.9 (4.2–11.1) |